Compare Charles River Laboratories Intl. Inc (CRL) vs First Citizens BancShares Inc (FCNCA) Price & Performance

Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.

Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.

First Citizens BancShares (FCNCA) trades at $2,106.06, up 0.64% with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $44.86 exceeding expectations by 13.4%. Recent developments include expansion of commercial banking capabilities and the planned retirement of the Silicon Valley Bank brand name in Q4 2026. The company maintains solid profitability with a 24.35% net income margin and 10.5% ROE, supported by $9.25B in revenue for 2025.

FCNCA presents a mixed investment case with strong fundamentals but cautious analyst sentiment. While valuation appears reasonable at 11.89 P/E and 1.18 P/B ratios, the majority of analysts (81.82%) maintain Hold ratings. Key opportunities include continued earnings momentum and strategic brand alignment, while risks involve margin pressure and credit exposure in the tech sector. The consensus price target of $2,320 suggests modest upside potential from current levels.